Phase II trials, HERACLES and MyPathway studies demonstrate the clinical benefit with objective response rates (ORR) of 30% to 38% for patients with HER2-overexpressing CRC who are treated with a combination of trastuzumab plus lapatinib or trastuzumab plus pertuzumab, respectively [21,22]. The gene discussed is ERBB2; the disease is colorectal carcinoma.